New Insight: A Look at Gildeuretinol (ALK-001) for Stargardt Disease w/ Seemi Khan, MD

In the latest episode of New Insight with Veeral Sheth, MD, host Veeral Sheth, MD, director of clinical research at University Retina, speaks with Seemi Khan, chief medical officer at Alkeus Pharmaceuticals, on the company’s lead candidate being evaluated in clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Gildeuretinol is a novel molecule designed as a specialized form of deuterated vitamin A to reduce the dimerization of vitamin A without disrupting vision. The therapy has received Breakthrough and Orphan Drug designations from the US Food and Drug Administration (FDA). Listen to the conversation between experts on Khan’s background in the pharmaceutical industry, including time spent at Abbott, Abbvie, and Quark Pharmaceuticals, her experience bringing treatments to patients with rare diseases, and the impressive data from gildeuretinol in the TEASE clinical trial program for a currently unmet need.Episode Highlights0:07 Episode Intro0:57 Seemi Khan's background4:38 Mechanism of action of gildeuretinol7:22 Patient populations9:00 TEASE clinical trial program14:37 Gildeuretinol in GA16:32 Safety data18:47 Next steps for Alkeus22:28 ConclusionCheck out more ophthalmology coverage at HCPLive.com!